top of page
Breaking the rules of
Work within the Davies Group draws upon an established knowledge of asymmetric synthesis and catalysis to discover and develop novel methodologies -- with the ultimate goal of defining enabling technologies for the chemical community.
The Davies group is a member of the Beyond CCF: Catalysis Innovation Consortium and the NSF Center for Selective C–H Functionalization, a research collaborative that aims to develop this emerging technology into a mainstream science.
NEWS & EVENTS
A Novel 7H-[1,2,4]Triazolo[3,4-b]thiadiazine-based Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Directed toward Treatment of Cystic Fibrosis
Congratulations to Will Tracy on his collaborative work on CFTR Potentiators in ACS Med. Chem. Lett.! Read all about it at https://doi.org/10.1021/acsmedchemlett.3c00155.
Dirhodium catalysts lie at the heart of the research within the Davies group. Their unique properties allow the modular construction of catalysts that can be fine tuned in their steric, electronic, and stereochemical properties. Browse our research pages to discover the powerful transformations that we have discovered, allowing the construction of high value scaffolds from simple chemicals.
bottom of page